The financials
Nurix Therapeutics, Inc. by the numbers
Nurix Therapeutics, Inc. (NRIX) reported revenue of $9.0M in Q2 2026 (quarter ended May 31, 2026), down 79% from the same quarter a year earlier. That came with net loss of $90M. For the full year FY2025, revenue was $84M (+54% year on year) and net income −$264M. Its largest product in 2026-Q1 was License at $30M, 83% of the disclosed total, just ahead of Collaboration at 17%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $9.0M | $44M | −79% |
| Operating income | −$94M | −$48M | n/a |
| Net income | −$90M | −$43M | n/a |
| Diluted EPS | −$0.81 | −$0.52 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License | $30M | 83% |
| Collaboration | $6.3M | 17% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $9.0M (-75%)
Collaboration grew -36% year on yearLicense -100% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$9.0M$9.0MQoQ +45%year on year -36%+45%-36%
- License$0.00$0.00QoQ -100%year on year -100%-100%-100%